The evolution of drug resistance in clinical isolates of candida albicans

eLife

Volumn 2015, Issue 4, 2015, Pages 1-27

  Ford, Christopher B ^a   Funt, Jason M ^a   Abbey, Darren ^c   Issi, Luca ^d   Guiducci, Candace ^a   Martinez, Diego A ^a   Delorey, Toni ^a   Li, Bi Yu ^a   White, Theodore ^e   Cuomo, Christina ^a   Rao, Reeta P ^d   Berman, Judith ^c,f   Thompson, Dawn A ^a   Regev, Aviv ^a,b  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d Life Science and Bioengineering Center   (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^f TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CLOTRIMAZOLE; FLUCONAZOLE;

ANEUPLOIDY; ANTIBIOTIC RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CELL ADHESION; CLINICAL ARTICLE; CLONAL VARIATION; COPY NUMBER VARIATION; FILAMENTOUS FUNGUS; FLOW CYTOMETRY; FUNGAL VIRULENCE; FUNGUS ISOLATION; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; NEXT GENERATION SEQUENCING; NONHUMAN; POINT MUTATION; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL; SYSTEMIC ACQUIRED RESISTANCE; THRUSH; ADHESION; ANTIFUNGAL RESISTANCE; CANDIDIASIS; DNA SEQUENCE; DRUG EFFECTS; GENETICS; HOST PATHOGEN INTERACTION; HUMAN GENOME; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR EVOLUTION; MUTATION; PHENOTYPE; REPRODUCTIVE FITNESS; VIRULENCE;

CANDIDA ALBICANS;

ADHESIVENESS; ANEUPLOIDY; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; EVOLUTION, MOLECULAR; FLUCONAZOLE; GENETIC FITNESS; GENOME, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; LOSS OF HETEROZYGOSITY; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; VIRULENCE;

EID: 84964695807     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.00662     Document Type: Article

References (90)

1. Alby K, Bennett RJ. 2009. Stress-induced phenotypic switching in Candida albicans. Molecular Biology of the Cell 20:3178–3191. doi: 10.1091/mbc.E09-01-0040.
2. Arnaud MB, Costanzo MC, Shah P, Skrzypek MS, Sherlock G. 2009. Gene Ontology and the annotation of pathogen genomes: the case of Candida albicans. Trends in Microbiology 17:295–303. doi: 10.1016/j.tim.2009.04.007.
3. Asai K, Tsuchimori N, Okonogi K, Perfect JR, Gotoh O, Yoshida Y. 1999. Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450. Antimicrobial Agents and Chemotherapy 43:1163–1169.
4. Bennett RJ, Johnson AD. 2005. Mating in Candida albicans and the search for a sexual cycle. Annual Review of Microbiology 59:233–255. doi: 10.1146/annurev.micro.59.030804.121310.
5. Björkman J, Andersson DI. 2000. The cost of antibiotic resistance from a bacterial perspective. Drug Resistance Updates 3:237–245. doi: 10.1054/drup.2000.0147.
6. Bonangelino CJ, Chavez EM, Bonifacino JS. 2002. Genomic screen for vacuolar protein sorting genes in Saccharomyces cerevisiae. Molecular Biology of the Cell 13:2486–2501. doi: 10.1091/mbc.02-01-0005.
7. Brunet JP, Tamayo P, Golub TR, Mesirov JP. 2004. Metagenes and molecular pattern discovery using matrix factorization. Proceedings of the National Academy of Sciences of USA 101:4164–4169. doi: 10.1073/pnas.0308531101.
8. Butler G, Rasmussen MD, Lin MF, Santos MA, Sakthikumar S, Munro CA, Grabherr M, Forche A, Reedy JL, Agrafioti I, Arnaud MB, Bates S, Brown AJ, Brunke S, Costanzo MC, Fitzpatrick DA, de Groot PW, Harris D, Hoyer LL, Hube B, Klis FM, Kodira C, Lennard N, Logue ME, Martin R, Neiman AM, Nikolaou E, Quail MA, Quinn J, Santos MC, Schmitzberger FF, Sherlock G, Shah P, Silverstein KA, Skrzypek MS, Soll D, Staggs R, Stansfield I, Stumpf MP, Sudbery PE, Srikantha T, Zeng Q, Berman J, Berriman M, Heitman J, Gow NA, Lorenz MC, Birren BW, Kellis M, Cuomo CA. 2009. Evolution of pathogenicity and sexual reproduction in eight Candida genomes. Nature 459:657–662. doi: 10.1038/nature08064.
9. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. 2001. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. Journal of Bacteriology 183:5385–5394. doi: 10.1128/JB.183.18.5385-5394.2001.
10. Chang SL, Lai HY, Tung SY, Leu JY. 2013. Dynamic large-scale chromosomal rearrangements fuel rapid adaptation in yeast populations. PLOS Genetics 9:e1003232. doi: 10.1371/journal.pgen.1003232.
11. Charles PE, Doise JM, Quenot JP, Aube H, Dalle F, Chavanet P, Milesi N, Aho LS, Portier H, Blettery B. 2003. Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Medicine 29:2162–2169. doi: 10.1007/s00134-003-2002-x.
12. Connolly LA, Riccombeni A, Grózer Z, Holland LM, Lynch DB, Andes DR, Butler G. 2013. The APSES transcription factor Efg1 is a global regulator that controls morphogenesis and biofilm formation in Candida parapsilosis. Molecular Microbiology 90:36–53. doi: 10.1111/mmi.12345.
13. Coste A, Turner V, Ischer F, Morschhauser J, Forche A, Selmecki A, Berman J, Bille J, Sanglard D. 2006. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 172:2139–2156. doi: 10.1534/genetics.105.054767.
14. Cowen LE, Anderson JB, Kohn LM. 2002. Evolution of drug resistance in Candida albicans. Annual Review of Microbiology 56:139–165. doi: 10.1146/annurev.micro.56.012302.160907.
15. Cowen LE, Lindquist S. 2005. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309:2185–2189. doi: 10.1126/science.1118370.
16. De Groot PW, Hellingwerf KJ, Klis FM. 2003. Genome-wide identification of fungal GPI proteins. Yeast 20: 781–796. doi: 10.1002/yea.1007.
17. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, Kalicki-Veizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, Link DC, Tomasson MH, Shannon WD, Payton JE, Kulkarni S, Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF. 2012. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481:506–510. doi: 10.1038/nature10738.
18. Dunkel N, Blass J, Rogers PD, Morschhauser J. 2008. Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Molecular Microbiology 69:827–840. doi: 10.1111/j.1365-2958.2008.06309.x.
19. Dunkel N, Morschhauser J. 2011. Loss of heterozygosity at an unlinked genomic locus is responsible for the phenotype of a Candida albicans sap4Δ sap5Δ sap6Δ mutant. Eukaryotic Cell 10:54–62. doi: 10.1128/EC.00281-10.
20. Forche A, Abbey D, Pisithkul T, Weinzierl MA, Ringstrom T, Bruck D, Berman J. 2011. Stress alters rates and types of loss of heterozygosity in Candida albicans. mBio 2. doi: 10.1128/mBio.00129-11.
21. Forche A, Alby K, Schaefer D, Johnson AD, Berman J, Bennett RJ. 2008. The parasexual cycle in Candida albicans provides an alternative pathway to meiosis for the formation of recombinant strains. PLOS Biology 6:e110. doi: 10.1371/journal.pbio.0060110.
22. Forche A, Magee PT, Magee BB, May G. 2004. Genome-wide single-nucleotide polymorphism map for Candida albicans. Eukaryotic Cell 3:705–714. doi: 10.1128/EC.3.3.705-714.2004.
23. Forche A, Magee PT, Selmecki A, Berman J, May G. 2009. Evolution in Candida albicans populations during a single passage through a mouse host. Genetics 182:799–811. doi: 10.1534/genetics.109.103325.
24. Forche A, May G, Magee PT. 2005. Demonstration of loss of heterozygosity by single-nucleotide polymorphism microarray analysis and alterations in strain morphology in Candida albicans strains during infection. Eukaryotic Cell 4:156–165. doi: 10.1128/EC.4.1.156-165.2005.
25. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. 2006. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312:1944–1946. doi: 10.1126/science.1124410.
26. Galhardo RS, Hastings PJ, Rosenberg SM. 2007. Mutation as a stress response and the regulation of evolvability. Critical Reviews in Biochemistry and Molecular Biology 42:399–435. doi: 10.1080/10409230701648502.
27. Gemayel R, Vinces MD, Legendre M, Verstrepen KJ. 2010. Variable tandem repeats accelerate evolution of coding and regulatory sequences. Annual Review of Genetics 44:445–477. doi: 10.1146/annurev-genet-072610-155046.
28. Gow NA, Hube B. 2012. Importance of the Candida albicans cell wall during commensalism and infection. Current Opinion in Microbiology 15:406–412. doi: 10.1016/j.mib.2012.04.005.
29. Goyard S, Knechtle P, Chauvel M, Mallet A, Prévost MC, Proux C, Coppée JY, Schwarz P, Dromer F, Park H, Filler SG, Janbon G, d'Enfert C. 2008. The Yak1 kinase is involved in the initiation and maintenance of hyphal growth in Candida albicans. Molecular Biology of the Cell 19:2251–2266. doi: 10.1091/mbc.E07-09-0960.
30. Grabherr MG, Haas BJ, Yassour M, Levin JZ, Thompson DA, Amit I, Adiconis X, Fan L, Raychowdhury R, Zeng Q, Chen Z, Mauceli E, Hacohen N, Gnirke A, Rhind N, di Palma F, Birren BW, Nusbaum C, Lindblad-Toh K, Friedman N, Regev A. 2011. Full-length transcriptome assembly from RNA-Seq data without a reference genome. Nature Biotechnology 29:644–652. doi: 10.1038/nbt.1883.
31. Gresham D, Desai MM, Tucker CM, Jenq HT, Pai DA, Ward A, DeSevo CG, Botstein D, Dunham MJ. 2008. The repertoire and dynamics of evolutionary adaptations to controlled nutrient-limited environments in yeast. PLOS Genetics 4. doi: 10.1371/Journal.Pgen.1000303.
32. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D. 2003. Attributable mortality of nosocomial candidemia, revisited. Clinical Infectious Diseases 37:1172–1177. doi: 10.1086/378745.
33. Hickman MA, Zeng G, Forche A, Hirakawa MP, Abbey D, Harrison BD, Berman J. 2013. The 'obligate diploid' Candida albicans forms mating-competent haploids. Nature 494:55–59. doi: 10.1038/nature11865.
34. Hoyer LL, Green CB, Oh SH, Zhao X. 2008. Discovering the secrets of the Candida albicans agglutinin-like sequence (ALS) gene family–a sticky pursuit. Medical Mycology 46:1–15. doi: 10.1080/13693780701435317.
35. Hoyer LL, Payne TL, Bell M, Myers AM, Scherer S. 1998. Candida albicans ALS3 and insights into the nature of the ALS gene family. Current Genetics 33:451–459. doi: 10.1007/s002940050359.
36. Inglis DO, Arnaud MB, Binkley J, Shah P, Skrzypek MS, Wymore F, Sherlock G. 2012. The Candida genome database incorporates multiple Candida species: multispecies search and analysis tools with curated gene and protein information for Candida albicans and Candida glabrata. Nucleic Acids Research 40:D667–D674. doi: 10.1093/nar/gkr945.
37. Inglis DO, Skrzypek MS, Arnaud MB, Binkley J, Shah P, Wymore F, Sherlock G. 2013. Improved gene ontology annotation for biofilm formation, filamentous growth, and phenotypic switching in Candida albicans. Eukaryotic Cell 12:101–108. doi: 10.1128/EC.00238-12.
38. Jain C, Pastor K, Gonzalez AY, Lorenz MC, Rao RP. 2013. The role of Candida albicans AP-1 protein against host derived ROS in in vivo models of infection. Virulence 4:67–76. doi: 10.4161/viru.22700.
39. Jain C, Yun M, Politz SM, Rao RP. 2009. A pathogenesis assay using Saccharomyces cerevisiae and Caenorhabditis elegans reveals novel roles for yeast AP-1, Yap1, and host dual oxidase BLI-3 in fungal pathogenesis. Eukaryotic Cell 8:1218–1227. doi: 10.1128/EC.00367-08.
40. Kemp HA, Sprague GF Jr. 2003. Far3 and five interacting proteins prevent premature recovery from pheromone arrest in the budding yeast Saccharomyces cerevisiae. Molecular and Cellular Biology 23:1750–1763. doi: 10.1128/MCB.23.5.1750-1763.2003.
41. Kim J, Sudbery P. 2011. Candida albicans, a major human fungal pathogen. Journal of microbiology 49:171–177. doi: 10.1007/s12275-011-1064-7.
42. Kumamoto CA, Pierce JV. 2011. Immunosensing during colonization by Candida albicans: does it take a village to colonize the intestine? Trends in Microbiology 19:263–267. doi: 10.1016/j.tim.2011.01.009.
43. Kumamoto CA, Vinces MD. 2005. Alternative Candida albicans lifestyles: growth on surfaces. Annual Review of Microbiology 59:113–133. doi: 10.1146/annurev.micro.59.030804.121034.
44. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, Wan Y, Zhang W, Shukla SA, Vartanov A, Fernandes SM, Saksena G, Cibulskis K, Tesar B, Gabriel S, Hacohen N, Meyerson M, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ. 2013. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152:714–726. doi: 10.1016/j.cell.2013.01.019.
45. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25:1754–1760. doi: 10.1093/bioinformatics/btp324.
46. Lo HJ, Köhler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink GR. 1997. Nonfilamentous C. albicans mutants are avirulent. Cell 90:939–949. doi: 10.1016/s0092-8674(00)80358-x.
47. Loeb JD, Sepulveda-Becerra M, Hazan I, Liu H. 1999. A G1 cyclin is necessary for maintenance of filamentous growth in Candida albicans. Molecular and Cellular Biology 19:4019–4027.
48. MacPherson S, Akache B, Weber S, De Deken X, Raymond M, Turcotte B. 2005. Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. Antimicrobial Agents and Chemotherapy 49:1745–1752. doi: 10.1128/AAC.49.5.1745-1752.2005.
49. Mardis ER. 2008. The impact of next-generation sequencing technology on genetics. Trends in Genetics 24:133–141. doi: 10.1016/j.tig.2007.12.007.
50. Marichal P, Koymans L, Willemsens S, Bellens D, Verhasselt P, Luyten W, Borgers M, Ramaekers FC, Odds FC, Bossche HV. 1999. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Nature Reviews Microbiology 145:2701–2713.
51. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. 2010. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Research 20:1297–1303. doi: 10.1101/gr.107524.110.
52. Nobile CJ, Fox EP, Nett JE, Sorrells TR, Mitrovich QM, Hernday AD, Johnson AD. 2012. A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell 148:126–138. doi: 10.1016/j.cell.2011.10.048.
53. Nobile CJ, Mitchell AP. 2005. Regulation of cell-surface genes and biofilm formation by the C. albicans transcription factor Bcr1p. Current Biology 15:1150–1155. doi: 10.1016/j.cub.2005.05.047.
54. Noble SM, French S, Kohn LA, Chen V, Johnson AD. 2010. Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity. Nature Genetics 42:590–598. doi: 10.1038/ng.605.
55. Oliver BG, Song JL, Choiniere JH, White TC. 2007. cis-Acting elements within the Candida albicans ERG11 promoter mediate the azole response through transcription factor Upc2p. Eukaryotic Cell 6:2231–2239. doi: 10.1128/EC.00331-06.
56. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Dismukes WE. 2003. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clinical Infectious Diseases 37:634–643. doi: 10.1086/376906.
57. Pavelka N, Rancati G, Zhu J, Bradford WD, Saraf A, Florens L, Sanderson BW, Hattem GL, Li R. 2010. Aneuploidy confers quantitative proteome changes and phenotypic variation in budding yeast. Nature 468:321–325. doi: 10.1038/nature09529.
58. Perea S, López-Ribot JL, Kirkpatrick WR, McAtee RK, Santillan RA, Martinez M, Calabrese D, Sanglard D, Patterson TF. 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy 45:2676–2684. doi: 10.1128/AAC.45.10.2676-2684.2001.
59. Pfaller MA, Lockhart SR, Pujol C, Swails-Wenger JA, Messer SA, Edmond MB, Jones RN, Wenzel RP, Soll DR. 1998. Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates. Journal of Clinical Microbiology 36:1518–1529.
60. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. 1994. Candida colonization and subsequent infections in critically ill surgical patients. Annals of Surgery 220:751–758. doi: 10.1097/00000658-199412000-00008.
61. Podlaha O, Riester M, De S, Michor F. 2012. Evolution of the cancer genome. Trends in Genetics 28:155–163. doi: 10.1016/j.tig.2012.01.003.
62. Ponder RG, Fonville NC, Rosenberg SM. 2005. A switch from high-fidelity to error-prone DNA double-strand break repair underlies stress-induced mutation. Molecular Cell 19:791–804. doi: 10.1016/j.molcel.2005.07.025.
63. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. 2006. GenePattern 2.0. Nature Genetics 38:500–501. doi: 10.1038/ng0506-500.
64. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. The New England Journal of Medicine 331:1325–1330. doi: 10.1056/NEJM199411173312001.
65. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, Brass C, Vazquez JA, Chapman SW, Horowitz HW, Zervos M, McKinsey D, Lee J, Babinchak T, Bradsher RW, Cleary JD, Cohen DM, Danziger L, Goldman M, Goodman J, Hilton E, Hyslop NE, Kett DH, Lutz J, Rubin RH, Scheld WM, Schuster M, Simmons B, Stein DK, Washburn RG, Mautner L, Chu TC, Panzer H, Rosenstein RB, Booth J, National Institute of Allergy and Infectious Diseases Mycoses Study Group. 2003. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clinical Infectious Diseases 36:1221–1228. doi: 10.1086/374850.
66. Reynolds TB, Fink GR. 2001. Bakers' yeast, a model for fungal biofilm formation. Science 291:878–881. doi: 10.1126/science.291.5505.878.
67. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. 2011. Integrative genomics viewer. Nature Biotechnology 29:24–26. doi: 10.1038/nbt.1754.
68. Rosenberg SM. 2011. Stress-induced loss of heterozygosity in Candida: a possible missing link in the ability to evolve. mBio 2. doi: 10.1128/mBio.00200-11.
69. Santos MA, Moura G, Massey SE, Tuite MF. 2004. Driving change: the evolution of alternative genetic codes. Trends in Genetics 20:95–102. doi: 10.1016/j.tig.2003.12.009.
70. Sasse C, Dunkel N, Schafer T, Schneider S, Dierolf F, Ohlsen K, Morschhauser J. 2012. The stepwise acquisition of fluconazole resistance mutations causes a gradual loss of fitness in Candida albicans. Molecular Microbiology 86:539–556. doi: 10.1111/j.1365-2958.2012.08210.x.
71. Schubert S, Popp C, Rogers PD, Morschhäuser J. 2011. Functional dissection of a Candida albicans zinc cluster transcription factor, the multidrug resistance regulator Mrr1. Eukaryotic Cell 10:1110–1121. doi: 10.1128/EC.05100-11.
72. Selmecki A, Forche A, Berman J. 2006. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313:367–370. doi: 10.1126/science.1128242.
73. Selmecki A, Forche A, Berman J. 2010. Genomic plasticity of the human fungal pathogen Candida albicans. Eukaryotic Cell 9:991–1008. doi: 10.1128/EC.00060-10.
74. Selmecki A, Gerami-Nejad M, Paulson C, Forche A, Berman J. 2008. An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Molecular Microbiology 68:624–641. doi: 10.1111/j.1365-2958.2008.06176.x.
75. Selmecki AM, Dulmage K, Cowen LE, Anderson JB, Berman J. 2009. Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. PLOS Genetics 5:e1000705. doi: 10.1371/journal.pgen.1000705.
76. Sheppard DC, Yeaman MR, Welch WH, Phan QT, Fu Y, Ibrahim AS, Edwards JE Jr. 2004. Functional and structural diversity in the Als protein family of Candida albicans. Journal of Biological Chemistry 279:30480–30489. doi: 10.1074/jbc.M401929200.
77. Singh-Babak SD, Babak T, Diezmann S, Hill JA, Xie JL, Chen YL, Poutanen SM, Rennie RP, Heitman J, Cowen LE. 2012. Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. PLOS Pathogens 8:e1002718. doi: 10.1371/journal.ppat.1002718.
78. Storm N, Darnhofer-Patel B, van den Boom D, Rodi CP. 2003. MALDI-TOF mass spectrometry-based SNP genotyping. Methods in Molecular Biology 212:241–262.
79. Swofford DL. 2002. PAUP*. Phylogenetic analysis using parsimony (*and other methods). Sunderland, MA: Sinauer Associates.
80. Tang YC, Amon A. 2013. Gene copy-number alterations: a cost-benefit analysis. Cell 152:394–405. doi: 10.1016/j.cell.2012.11.043.
81. Thompson DA, Desai MM, Murray AW. 2006. Ploidy controls the success of mutators and nature of mutations during budding yeast evolution. Current Biology 16:1581–1590. doi: 10.1016/j.cub.2006.06.070.
82. Torres EM, Dephoure N, Panneerselvam A, Tucker CM, Whittaker CA, Gygi SP, Amon A. 2010. Identification of aneuploidy-tolerating mutations. Cell 143:71–83. doi: 10.1016/j.cell.2010.08.038.
83. Uhl MA, Biery M, Craig N, Johnson AD. 2003. Haploinsufficiency-based large-scale forward genetic analysis of filamentous growth in the diploid human fungal pathogen C.albicans. The EMBO Journal 22:2668–2678. doi: 10.1093/emboj/cdg256.
84. Verstrepen KJ, Jansen A, Lewitter F, Fink GR. 2005. Intragenic tandem repeats generate functional variability. Nature Genetics 37:986–990. doi: 10.1038/ng1618.
85. White TC. 1997a. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrobial Agents and Chemotherapy 41:1482–1487.
86. White TC. 1997b. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans. Antimicrobial Agents and Chemotherapy 41:1488–1494.
87. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. 2002. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrobial Agents and Chemotherapy 46:1704–1713. doi: 10.1128/AAC.46.6.1704-1713.2002.
88. Wisplinghoff H, Seifert H, Tallent SM, Bischoff T, Wenzel RP, Edmond MB. 2003. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. The Pediatric Infectious Disease Journal 22:686–691. doi: 10.1097/01.inf.0000078159.53132.40.
89. Yona AH, Manor YS, Herbst RH, Romano GH, Mitchell A, Kupiec M, Pilpel Y, Dahan O. 2012. Chromosomal duplication is a transient evolutionary solution to stress. Proceedings of the National Academy of Sciences of USA 109:21010–21015. doi: 10.1073/pnas.1211150109.
90. Zakikhany K, Naglik JR, Schmidt-Westhausen A, Holland G, Schaller M, Hube B. 2007. In vivo transcript profiling of Candida albicans identifies a gene essential for interepithelial dissemination. Cellular Microbiology 9: 2938–2954. doi: 10.1111/j.1462-5822.2007.01009.x.